Advertisement

Pankreaskarzinom

  • M. Treiber
  • M. J. Eble
  • R. Krempien
Chapter

Zusammenfassung

Es gibt kein typisches Frühsymptom des Pankreaskarzinoms.

Literatur

  1. Abe M, Shibamoto Y, Takahashi M (1987) Intraoperative radiotherapy in carcinoma of the stomach and pancreas. World J Surg 11:459–464PubMedCrossRefGoogle Scholar
  2. Beger HG, Poch B, Schwarz M et al (2003) Pancreatic cancer: The relative importance of neoadjuvant therapy. Chirurg 74:202–207PubMedCrossRefGoogle Scholar
  3. Brunner TB, Grabenbauer GG, Kastl S et al. (2000) Preoperative Chemoradiation in Locally Advanced Pancreatic Carcinoma: A Phase II Study. Onkologie 23:436–442PubMedCrossRefGoogle Scholar
  4. Chandler NM, Canete JJ, Stuart KE et al (2003) Preoperative chemoradiation in respectable pancreatic cancer. J Hepatobilary Pancreat Surg 10:61–66Google Scholar
  5. Crane CH, Abbruzzese JL, Evans DB et al. (2002) Is the therapeutic index better with gemcitabine-based chemoradiation than with 5-fluorouracil-based chemoradiation in locally advanced pancreatic cancer? Int J Radiat Oncol Biol Phys 52:1293–1302PubMedCrossRefGoogle Scholar
  6. Crane CH, Beddar AS, Evans DB (2003) The role of intraoperative radiotherapy in pancreatic cancer. Surg Oncol Clin N Am 12:965–977PubMedCrossRefGoogle Scholar
  7. GITSG (1979) A multi-institutional comparative trial of radiation therapy alone and in combination with 5-fluorouracil for locally unresectable pancreatic carcinoma. The Gastrointestinal Tumor Study Group. Ann Surg 189:205–208Google Scholar
  8. Gunderson LL, Martin JK, Kvols et al. (1987) Intraoperative and external beam irradiation +/− 5-FU for locally advanced pancreatic cancer. Int J Radiat Oncol Biol Phys 13:319–329PubMedCrossRefGoogle Scholar
  9. Jackson AS, Jain P, Watkins GR (2010) Efficacy and tolerability of limited field radiotherapy with concurrent capecitabine in locally advanced pancreatic cancer. Clin Oncol (R Coll Radiol) 22(7):570–577CrossRefGoogle Scholar
  10. Kalser MH, Ellenberg SS (1985) Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 120:899–903PubMedCrossRefGoogle Scholar
  11. Kastl S, Brunner T, Herrmann O (2000) Neoadjuvant radiochemotherapy in advanced primarilynon-resectable carcinomas of the pancreas. Eur J Surg Onc 26:578–582CrossRefGoogle Scholar
  12. Klinkenbijl JH, Jeekel J, Sahmoud T et al. (1999) Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC gastrointestinal tract cancer cooperative group. Ann Surg 230:776–782; discussion 782–784CrossRefGoogle Scholar
  13. Knaebel HP, Marten A, Schmidt J et al (2005) Phase-III-trial of postoperative cisplatin, interferon alpha-2b and 5-FU combined with external radiation treatment versus 5-FU alone for patients with resected pancreatic adenocarcinoma – CapRI: study protocol. BMC Cancer 5:37PubMedCrossRefGoogle Scholar
  14. Moertel CG, Frytak S, Hahn RG et al. (1981) Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study Group. Cancer 48:1705–1710PubMedCrossRefGoogle Scholar
  15. Neoptolemos JP, Dunn JA, Stocken DD et al. (2001) Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 358:1565–1566CrossRefGoogle Scholar
  16. Ozawa F, Friess H, Büchler MW (2001) Treatment of pancreatic cancer: the role of surgery. Dig Dis 19(1):47–56PubMedCrossRefGoogle Scholar
  17. Picozzi VJ, Kozarek RA, Traverso LW (2003) Interferon-based adjuvant chemoradiation therapy after pancreaticduodenectomy for pancreatic adenocarcinoma. Am J Surg 185:476–480PubMedCrossRefGoogle Scholar
  18. Turrini O, Ychou M, Moureau-Zabotto L (2010) Neoadjuvant docetaxel-based chemoradiation for resectable adenocarcinoma of the pancreas: New neoadjuvant regimen was safe and provided an interesting pathologic response. Eur J Surg Oncol 36(10):987–992PubMedCrossRefGoogle Scholar
  19. Valentini V, Calvo F, Reni M et al (2009) Intra-operative radiotherapy (IORT) in pancreatic cancer: joint analysis of the ISIORT-Europe experience. Radiother Oncol 91(1):54–59PubMedCrossRefGoogle Scholar
  20. Van Laethem JL, Hammel P, Mornex F et al (2010) Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study. J Clin Oncol 28(29): 4450–4456PubMedCrossRefGoogle Scholar
  21. Whittington R, Bryer MP, Haller DG et al. (1991) Adjuvant therapy of resected adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys 21:1137PubMedCrossRefGoogle Scholar
  22. Wilkowsli R, Thoma M, Heinemann V (2003) Radiochemotherapie mit Gemcitabin und Cisplatin bei Pankreaskarzinom – durchführbar und effektiv. Strahlenther Onkol 2:78–86CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • M. Treiber
    • 1
  • M. J. Eble
    • 2
  • R. Krempien
    • 3
  1. 1.Radioonkologie, Caritas Klinikum Saarbrücken St. TheresiaSaarbrückenDeutschland
  2. 2.Klinik für Strahlentherapie, Universitätsklinik AachenAachenDeutschland
  3. 3.Helios Kliniken GmbH, Klinik für StrahlentherapieBerlin-BuchDeutschland

Personalised recommendations